Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 32 of 95, showing 5 Applications out of 474 total, starting on record 156, ending on 160

# Protocol No Study Title Investigator(s) & Site(s)

156.

ECCT/17/07/01   ABCD
    Antibiotics for Children with Severe Diarrhea Trial   
Principal Investigator(s)
1. Judd Walson
Site(s) in Kenya
1. Rongo Sub-County Hospital (Migori county)
2. Ndhiwa Sub-County Hospital (Homa Bay county)
3. Rachuonyo Sub-County Hospital (Homa Bay county)
4. Isebania Sub-County Hospital (Migori county)
5. Awendo Sub-County Hospital (Migori county)
6. Mbita Sub-County Hospital (Homa Bay county)
 
View

157.

ECCT/17/08/01   A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults
    A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines.   
Principal Investigator(s)
1. Philip Bejon
Site(s) in Kenya
KEMRI Kilifi
 
View

158.

ECCT/17/08/02   IMPROVE (Improving PRegnancy Outcomes with intermittent PReVEntive treatment in Africa)
    IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine resistance areas in Kenya, Malawi and Tanzania: an international multi-centre 3-arm placebo-controlled trial   
Principal Investigator(s)
1. Simon Kariuki
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Rongo Sub-County Hospital (Migori county)
4. Ahero Sub-County Hospital (Kisumu county)
5. Rabuor Sub-County Hospital (Kisumu county)
 
View

159.

ECCT/17/08/03   Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.           
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI Siaya
 
View

160.

ECCT/17/08/04   P1081
    A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION:    NICHD P1081   
Principal Investigator(s)
1. FREDRICK KIPYEGON SAWE
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Clinical Research Centre.
 
View